Oncolytics Biotech ONCY
NASDAQ ONCY
$0.41 +0.03 (+7.81%)
At close: Nov 11, 2026 · 4:00 PM EST

Oncolytics Biotech (ONCY) EBITDA Margin (2009 - 2025)

Updated

Oncolytics Biotech (ONCY) posted EBITDA Margin of -760.93% for Q2 2017, down 1135.54 percentage points from 374.60% a year earlier.

Analysis

Oncolytics Biotech (ONCY) EBITDA Margin (2009 - 2025) Analysis & Trends

For the trailing twelve months through Jun 30, 2017, EBITDA Margin at Oncolytics Biotech was -802.07%, down 831.67 percentage points year-over-year; for FY2009, it came in at -5140.04%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 32.68%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 46.88%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 40.60%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 39.77%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 46.62%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 50.63%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 42.49%
10 Oncolytics Biotech 47.36 Mn 23.68 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -14,583.00%
Jun 30, 2025 -6,172.55%
Mar 31, 2025 -5,835.23%
Sep 30, 2024 -3,625.29%
Jun 30, 2018 -85.60%
Mar 31, 2018 -98.42%
Jun 30, 2017 -760.93%
Jun 30, 2016 -362.03%
Jun 30, 2010 -111.59%
Dec 31, 2009 -5,223.85%
API Access

Oncolytics Biotech EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ONCY&period=max&api_key=YOUR_API_KEY